Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$5.94
-$0.17(-2.86%)
At close: 4:00 PM EDT
$5.94
-$0.17(-2.86%)
Day’s Range― - ―
52-Week Range$4.91 - $15.09
Previous CloseN/A
Volume674.69K
Average Volume (3M)2.13M
Market Cap
$626.52M
Enterprise Value$748.32
Total Cash (Recent Filing)$143.84M
Total Debt (Recent Filing)$171.60M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 17, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding99,447,340
10 Day Avg. Volume2,563,913
30 Day Avg. Volume2,125,274
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside405.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$139.83M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionRapid gains in market share and prescriber adoption indicate that neffy is gaining commercial traction. Continued provider engagement could support durable product growth as awareness of needle-free epinephrine expands.
Strong Product EconomicsHealthy gross margins support the underlying economics of neffy and provide operating leverage as volumes increase. Manufacturing scale and improved execution could further strengthen contribution margins over the medium term.
Cost Discipline And RunwayA targeted commercial model and significant planned expense reduction could extend liquidity and narrow the path to breakeven. The $143.8 million of cash, equivalents and short-term investments provides funding for execution.
Bears Say
Heavy Losses And Cash BurnThe company remains deeply unprofitable and consumes substantial cash relative to its commercial scale. Persistent losses increase dependence on external financing and could delay breakeven if revenue growth or cost reductions fall short.
Fragile Balance SheetA sharply reduced equity cushion and high leverage limit financial flexibility. If operating losses continue, refinancing needs or additional equity issuance could create dilution risk and constrain investment in commercial and pipeline programs.
Payer And Revenue Realization FrictionPrior-authorization requirements can slow prescribing and add administrative barriers despite broad coverage. Gross-to-net deductions near 50% also reduce realized revenue, making sustained adoption and efficient selling essential to profitability.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $4.91 and its highest was $15.09 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $626.52M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 88 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.152.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,447,340 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -7.377%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (405.05% Upside)
$30.00 (405.05% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 71%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial momentum and a clear strategic reset with notable operational and financial challenges. Positive indicators include doubled overall market share (2.5% to 5%), an 8% share in field-targeted accounts, triple+ growth in unique prescribers, a completed sales-force expansion, hiring of an experienced CCO, and a plan to reduce cash-based SG&A by over 40% in H2 with a stated path to cash-flow breakeven by end of 2027. Offsetting these positives are high Q2 operating expenses (~$95.1M), elevated SG&A (~$77.6M), gross-to-net pressure near ~50%, manufacturing/short-dated inventory impacts on margins, payer prior-authorization friction (only ~57% without PA) and a modest delay in the CSU Phase IIb interim readout to Q1 2027. Overall, the company presented a constructive corrective plan but material execution and margin risks remain.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$30.00
▲(405.05% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
50.06% Insiders
6.93% Mutual Funds
17.75% Other Institutional Investors
15.88% Public Companies and
Individual Investors